

ARTICLE OPEN



Global estimates on the number of people blind or visually impaired by age-related macular degeneration: a meta-analysis from 2000 to 2020

Vision Loss Expert Group of the Global Burden of Disease Study* and the GBD 2019 Blindness and Vision Impairment Collaborators*

© The Author(s) 2024

BACKGROUND: We aimed to update estimates of global vision loss due to age-related macular degeneration (AMD).**METHODS:** We did a systematic review and meta-analysis of population-based surveys of eye diseases from January, 1980, to October, 2018. We fitted hierarchical models to estimate the prevalence of moderate and severe vision impairment (MSVI; presenting visual acuity from <6/18 to 3/60) and blindness (<3/60) caused by AMD, stratified by age, region, and year.**RESULTS:** In 2020, 1.85 million (95%UI: 1.35 to 2.43 million) people were estimated to be blind due to AMD, and another 6.23 million (95%UI: 5.04 to 7.58) with MSVI globally. High-income countries had the highest number of individuals with AMD-related blindness (0.60 million people; 0.46 to 0.77). The crude prevalence of AMD-related blindness in 2020 (among those aged ≥ 50 years) was 0.10% (0.07 to 0.12) globally, and the region with the highest prevalence of AMD-related blindness was North Africa/Middle East (0.22%; 0.16 to 0.30). Age-standardized prevalence (using the GBD 2019 data) of AMD-related MSVI in people aged ≥ 50 years in 2020 was 0.34% (0.27 to 0.41) globally, and the region with the highest prevalence of AMD-related MSVI was also North Africa/Middle East (0.55%; 0.44 to 0.68). From 2000 to 2020, the estimated crude prevalence of AMD-related blindness decreased globally by 19.29%, while the prevalence of MSVI increased by 10.08%.**CONCLUSIONS:** The estimated increase in the number of individuals with AMD-related blindness and MSVI globally urges the creation of novel treatment modalities and the expansion of rehabilitation services.Eye (2024) 38:2070–2082; <https://doi.org/10.1038/s41433-024-03050-z>**INTRODUCTION**

Age-related macular degeneration (AMD) is an acquired, degenerative disorder affecting the macula of older adults [1]. The disease is characterised by an array of features in the macular region, such as drusen (deposits that accumulate between the retinal pigment epithelium -RPE- and the Bruch's membrane), RPE cell depigmentation and proliferation, detachment of the RPE, loss of RPE cells and subretinal choroidal neovascularization [1], is categorized into a non-exudative (or "dry") stage and an exudative (or 'wet') stage. Older age, genetic background, family history, European ancestry, and smoking are considered risk factors for the development and progression of the disease [1].

Significant progress has been made in the treatment of the exudative stage of AMD over the last two decades due to the clinical introduction of intraocular injections of anti-vascular endothelial growth factor (VEGF) drugs [2]. Still, AMD has remained a challenge in global eye healthcare due to its relatively high prevalence in older adults and since most cases of the non-exudative stage, the most common form of AMD, cannot effectively be treated yet. AMD has a high importance as a cause of vision impairment and blindness [3], with sequels such as a reduction of the quality of life [4] and economic impact due to loss of productivity [5].

Although AMD-related blindness is a growing global problem due to population aging, its importance is not homogeneous

across world regions. In countries with a higher cataract surgical coverage (usually high-income countries), chronic eye conditions such as AMD account for a relatively more significant proportion of blindness [6].

To contribute to the World Health Organization (WHO) World Report on Vision [7] and the implementation of the recommendations generated [8], The Vision Loss Expert Group (VLEG) of the Global Burden of Disease (GBD) Study calculated estimates of the leading causes of vision impairment and blindness, like AMD [3, 9–11]. Such estimates are essential for monitoring, action planning, and advocacy [6]. In this systematic review, we aimed to update estimates of the global vision loss burden due to AMD, presenting estimates for 2020, temporal changes, and distribution by sex and world region.

METHODS

The data was arranged following a review of published population-focused studies on vision impairment and blindness by the VLEG. This review included studies published between Jan 1, 1980, and Oct 1, 2018, incorporating grey literature. After title and abstract screening, abstracts were sent to regional VLEG committees, where at least three ophthalmic epidemiologists independently scored studies for quality against inclusion criteria. They were asked to review and rate each study with a score of 1 (clearly a representative population-based study using a comprehensive

*Lists of authors and their affiliations appear at the end of the paper.

methodology), 2 (questionable representativeness and/or inadequately described or low-quality methodology), or 3 (definitely neither, warranting exclusion). Reviewers were asked to give their rationale for a rating of 2 or 3. A threshold for inclusion/exclusion was decided based on the average score of each study. Relevant studies from this review were combined with data from Rapid Assessment of Avoidable Blindness (RAAB) studies by VLEG. Data was also sourced from the US National Health and Nutrition Examination Survey 2007–2008 and the WHO Study on Global Ageing and Adult Health (SAGE Wave 1 2007–2010), contributed by the GBD team. A total of 252 studies contributed data on age-related macular degeneration and are grouped by geographical region in the Appendix. More detailed methods are published elsewhere [3, 10] and discussed in brief as follows.

VLEG pinpointed 137 studies and pulled data from 70 studies in their 2010 review and 67 additional studies in their 2014–18 review. Most of these studies were national or subnational cross-sectional surveys. VLEG also arranged to produce 5-year age-segregated RAAB data from the RAAB repository (www.raab.world). To qualify, studies met specific criteria: vision acuity data must be gathered through a test chart compatible with the Snellen scale, and the sample must represent the population. Subjective reports of vision loss were not included. The criteria for vision loss was defined by the International Classification of Diseases 11th edition as employed by WHO. It was based on the vision in the better eye upon presentation. Moderate vision loss was defined as a visual acuity of 6/60 or better but less than 6/18, severe vision loss as a visual acuity of 3/60 or better but less than 6/60, and blindness as a visual acuity of less than 3/60 or less than 10° visual field around central fixation (although the visual field definition was rarely used in population-based eye surveys).

We split the original data into several datasets, creating separate envelopes for each degree of vision loss (mild, moderate, and severe) and blindness. This data was then fed into a meta-regression tool designed by the Institute for Health Metrics and Evaluation (IHME) known as MR-BRT (meta-regression; Bayesian; regularised; trimmed) [12]. The benchmark for each severity level was presenting vision impairment.

When possible, data about uncorrected refractive errors were pulled straight from the data sources. If not, they were calculated by subtracting the best-corrected vision impairment from presenting vision impairment prevalence at each severity level. Other causes were factored into the best-corrected estimates for each level of vision impairment.

Our models for distance vision impairment and blindness were based on the most commonly reported causes found in the literature, and the minimum age for inclusion of data on AMD was 45 years. We created estimates of MSVI and blindness specific to location, year, age, and sex using Disease Modelling Meta-Regression (Dismod-MR) 2.1 [13]. Its data processing steps have been outlined elsewhere [3]. Briefly, Dismod-MR 2.1 models were run for all vision impairment by severity (moderate, severe, blindness) regardless of cause and, separately, for MSVI and blindness due to each modelled cause of vision impairment. Then, models of MSVI due to specific causes were split into moderate and severe estimates using the ratio of overall prevalence in the all-cause moderate presenting vision impairment and severe presenting vision impairment models. Next, prevalence estimates for all causes by severity were scaled to the models of all-cause prevalence by severity. This produced final estimates by age, sex, year, and location for each cause of vision impairment by severity. We age-standardised our estimates using the GBD standard population [14]. Hierarchical logistic regressions with mixed effects were applied using the R package RStanArm to assess the prevalence of blindness independently and MSVI across various country-age groups, structured within a five-tiered hierarchy. The blindness model was based on 270 studies, while the MSVI model included 245 studies, acknowledging that a single study might span multiple countries or years. This framework spanned 187 countries, grouped into 21 subregions and further into seven broader regions, culminating in an analysis of global-level effects. Data on blindness and MSVI due to AMD were presented by seven super-regions (Southeast Asia/East Asia/Oceania, Central Europe/Eastern Europe/Central Asia, High-income, Latin America and Caribbean, North Africa, and the Middle East, South Asia, and Sub-Saharan Africa) and globally. Data on other causes of vision impairment and blindness will be presented in separate publications.

RESULTS

In 2020, 1.85 million (all ages; 95% uncertainty interval (UI): 1.35 to 2.43 million) people were estimated to be blind due to AMD, with 664,000 (472,000 to 894,000) males and 1,185,000 (876,000 to 1,545,000) females affected (Tables 1, 2). AMD-related MSVI affected

6.23 million (95%UI: 5.04 to 7.58) individuals worldwide, among them 2,747,000 (2,207,000 to 3,377,000) males and 2,743,000 (2,202,000 to 3,371,000) females (Tables 1, 3).

High-income countries (0.60 million people; 0.46 to 0.77) accounted for the highest number of individuals with AMD-related blindness per world region, whereas the lowest number of individuals with presenting blindness due to AMD per world region was found in Central Europe / Eastern Europe / Central Asia combined (0.06 million people; 0.04 to 0.08) and Latin America and the Caribbean (0.07 million people; 0.50 to 0.1) (Table 1).

The crude prevalence of AMD-related blindness in those aged ≥ 50 years in 2020 was estimated as 0.10% (0.07 to 0.12) globally. The regions with the highest prevalence of blindness due to AMD were North Africa/Middle East, 0.22% (0.16 to 0.30) and Sub-Saharan Africa, 0.15% (0.11 to 0.20) (Supplementary Fig. 1). Age-standardized estimated prevalence of MSVI due to AMD in those aged ≥ 50 years in 2020 was 0.34% (0.27 to 0.41) globally, and the regions with the highest prevalence of MSVI due to AMD were also North Africa/Middle East (0.55%; 0.44 to 0.68) and Sub-Saharan Africa (0.50%; 0.40 to 0.61) (Table 1).

From 2000 to 2020, the estimated crude prevalence of blindness due to AMD decreased globally by 19.3% (19.6 to 19.0%), with a wide variety between regions, from -32.6% (-32.9 to -32.3%) in Southeast Asia, East Asia, and Oceania to +1.3% (0.9 to 1.7%) in Latin America and the Caribbean, the only region which showed an increase (Table 4). On the other hand, over the same period, the estimated crude prevalence of MSVI due to AMD increased globally by 10.1% (9.8 to 10.3%), with changes varying from -9.3% (-9.5 to -9.0%) in North Africa and Middle East to +7.2% (6.9 to 7.5%) in Southeast Asia, East Asia, and Oceania (Table 5). Figure 2 shows the estimated crude prevalence of MSVI due to AMD in 2020.

DISCUSSION

In 2020, AMD ranked second among the causes of irreversible blindness globally [3]. From 2000 to 2020, there was an estimated decrease in the prevalence of AMD-related blindness in all regions except Latin America and the Caribbean and an increase in the prevalence of AMD-related MSVI in all regions except North Africa, Middle East, and Sub-Saharan Africa, with wide discrepancies between regions. The global population growth and increasing life expectancy can explain the increasing number of individuals with AMD-related vision loss. Yet, the divergences in AMD prevalence and vision impairment necessitate extensive research to unravel the complex interplay of genetic factors, lifestyle choices, and access to healthcare services.

The prevalence of blindness and MSVI due to AMD is higher in older age groups, and countries with a growing life expectancy should take this information into account for better health service planning. But considering the current barriers to accessing AMD treatment and rehabilitation services in many regions, even a minor increase in absolute numbers might put pressure on the already overloaded public health systems. The reduced availability of ophthalmic services during the Covid-19 pandemic [15] and the economic impact that might be seen during the post-pandemic years can increase barriers in managing chronic eye conditions like AMD.

Dealing with AMD from a public health perspective is a complex task. First, although a trained ophthalmologist efficiently performs diagnosis, the availability and distribution of eye care professionals remain an issue in many parts of the world [16]. If well connected to public health initiatives, the growing use of telemedicine and artificial intelligence in eye care will likely reduce the percentage of those with undiagnosed AMD. Second, its first-line treatment, intravitreal anti-VEGF injection, can be expensive; its effect lasts only a few months and is only indicated for the wet form and, more recently, geographic atrophy [17]. And finally, those with MSVI and blindness due to AMD would benefit from rehabilitation services,

Table 1. Number of people (mean [95% UI]) with blindness (presenting visual acuity <3/60) or MSVI (presenting visual acuity <6/18, ≥3/60) due to AMD, the age-standardized prevalence (%) in people of all ages and aged ≥50 years (mean [95% UI]), and the percentage of all blindness or MSVI attributed to AMD (95% UI) in world regions in 2020.

World Region	2020, total population ('000 s)		Blindness due to AMD in 2020		MSVI due to AMD in 2020		MSVI due to AMD in 2020		MSVI due to AMD in 2020	
	(all ages)	(aged ≥ 50 years)	Number of people ('000 s) with blindness in 2020 (all ages)	Number of people ('000 s) with blindness in 2020 (aged ≥ 50 years)	Age-standardized prevalence of AMD blindness in 2020 (aged ≥ 50 years)	Percentage contribution by AMD to all causes of blindness in 2020 (aged ≥ 50 years)	Number of people ('000 s) with MSVI in 2020 (all ages)	Number of people ('000 s) with MSVI in 2020 (aged ≥ 50 years)	Age-standardized prevalence of AMD MSVI in 2020 (aged ≥ 50 years)	Percentage contribution by AMD to all causes of MSVI in 2020 (aged ≥ 50 years)
Global	7,890,000	1,898,000	1850 (1349–2434)	1841 (1340–2423)	0.10 (0.08–0.14)	4.30 (3.14–5.66)	6231 (5042–7587)	6221 (5029–7573)	0.34 (0.27–0.41)	2.11 (1.71–2.57)
Southeast Asia, East Asia, and Oceania	2,192,710	664,195	495 (342–680)	493 (339–673)	0.08 (0.06–0.11)	3.29 (2.27–4.51)	2762 (2211–3379)	2758 (2209–3376)	0.46 (0.37–0.56)	3.33 (2.66–4.07)
Central Europe, Eastern Europe, and Central Asia	417,291	137,758	62 (43–84)	62 (43–83)	0.04 (0.03–0.06)	4.43 (3.07–5.95)	228 (182–282)	227 (182–282)	0.16 (0.13–0.19)	1.27 (1.01–1.57)
Highincome	1,087,856	423,872	596 (456–769)	595 (455–768)	0.11 (0.08–0.14)	19.82 (15.17–25.60)	739 (584–917)	738 (584–917)	0.14 (0.11–0.17)	2.38 (1.88–2.95)
Latin America and Caribbean	601,551	136,738	71 (49–97)	71 (49–97)	0.05 (0.04–0.07)	1.95 (1.35–2.66)	333 (270–407)	332 (269–406)	0.25 (0.21–0.31)	1.36 (1.10–1.67)
North Africa and Middle East	631,727	105,278	195 (136–264)	194 (136–264)	0.22 (0.16–0.30)	6.31 (4.43–8.55)	493 (391–614)	492 (390–613)	0.55 (0.44–0.68)	2.26 (1.79–2.81)
South Asia	1,841,435	321,354	297 (200–423)	295 (199–421)	0.10 (0.07–0.15)	2.49 (1.68–3.55)	1220 (972–1510)	1217 (968–1507)	0.42 (0.34–0.51)	1.27 (1.01–1.57)
Sub-Saharan Africa	1,114,806	108,805	131 (92–178)	131 (91–178)	0.15 (0.11–0.20)	2.58 (1.81–3.51)	454 (360–565)	452 (358–564)	0.50 (0.40–0.61)	2.22 (1.76–2.77)

and their availability is also scarce [18]. The integration of education for those at a higher risk for developing AMD diagnosis, treatment, and rehabilitation, using a people-centred approach [7], could reduce the burden of AMD. Ideally, addressing AMD from a public health perspective demands a life course, people-centered approach recognizing the importance of early interventions and managing AMD co-morbidities. Preventative measures, such as anti-smoking campaigns targeted at adolescents and adults, could significantly impact the prevalence of AMD in the older population, given the well-established link between smoking and the progression of AMD.

In the healthcare continuum, involving primary care providers (PCPs) in AMD care could alleviate some current issues, especially in low-resource scenarios. They can serve as the initial touchpoint for patient education and promote awareness of AMD risk factors and early symptoms. For example, PCPs could play a crucial role in guiding patients through lifestyle changes that mitigate the risk of AMD, such as advocating smoking cessation, reinforcing the need for regular check-ups for those with diagnosed AMD or at a higher risk of having it, and potentially managing portable fundus cameras that could send images for remote ophthalmologists, or reinforcing the importance of compliance with follow-ups and treatment, and monitoring co-morbidities.

In addition to preventive care, there is a critical need to address the broader spectrum of challenges faced by individuals with AMD, particularly as they often experience other ocular and extraocular health issues. For instance, hearing impairment is a common co-morbidity that can compound the difficulties faced by those with vision loss, intensifying feelings of isolation and hindering effective communication. Moreover, individuals with vision impairment are at an increased risk of falls, which can lead to further physical injury and a decline in their quality of life [6]. Depression is another concern, with the loss of visual function significantly impacting mental health and the overall well-being of affected individuals [6].

The non-physician administration of anti-VEGF injections could be explored as a strategy to decentralize treatment, lowering costs and increasing access, while ensuring the safety and efficacy of such approaches through proper training and oversight [19]. Another option to be considered is conducting the injections within the same day of consultation, and same-day bilateral intravitreal injections to avoid multiple visits [20–22].

In the realm of age-related macular degeneration (AMD) treatments, emerging therapies like Pegcetacoplan and gene therapy offer renewed hope. Pegcetacoplan was recently the first drug approved by the Food and Drug Administration to treat geographic atrophy, the advanced stage of dry AMD known for its relentless progression of retinal cell degeneration and consequent permanent vision loss [17]. This novel drug specifically inhibits the C3 component of the immune system's complement pathway, a system implicated in the exacerbation of GA. In a recently published clinical trial, intravitreal injections of Pegcetacoplan could successfully slow GA progression. However, no differences in visual acuity between eyes injected with either Pegcetacoplan or sham injections were found [17].

Gene therapy presents a frontier approach in AMD treatment by introducing genetic material into cells to correct abnormal genes, suppress harmful gene expression, or produce beneficial proteins. This can involve various strategies, from replacing defective genes with functional ones, silencing genes contributing to disease progression to introducing new genes that could stop disease progression or repair damaged retinal tissue. Initial clinical trials have shed light on gene therapy's capacity for offering a sustained therapeutic effect, potentially simplifying treatment regimens by reducing the need for frequent injections, which are the current standard of care for wet AMD. Despite these promising developments, gene therapy for AMD remains in the experimental phase, and ongoing research is focused on

Table 2. Number of males and females with blindness (presenting visual acuity <3/60), and the age-standardized prevalence (% [95% UI]) of blindness due to AMD (all ages and people aged ≥50 years) in 2020.

World Region	Total Population 2020, total population ('000 s)	Total number of AMD blindness and aged-standardized AMD blindness in 2020 (all ages)			Total Number of AMD blindness and aged-standardized AMD blindness in people aged 50+ years in 2020		
		Number of males ('000 s) with AMD blindness in 2020	Number of females ('000 s) with AMD blindness in 2020	Age standardized prevalence of blindness in males in 2020	Number of males ('000 s) (50+ years) with AMD blindness in 2020	Age standardized prevalence of blindness in males in 2020	Age standardized prevalence of blindness in females in 2020
Global	7,890,000	664 (472–894)	1185 (876–1545)	0.0 (0.0–0.0)	660 (469–890)	0.1 (0.1–0.1)	0.1 (0.1–0.2)
Southeast Asia, East Asia, and Oceania	2,192,710	185 (128–257)	309 (214–424)	0.0 (0.0–0.0)	184 (126–254)	0.1 (0.1–0.1)	0.1 (0.1–0.1)
Central Europe, Eastern Europe, and Central Asia	417,291	20 (14–28)	42 (29–56)	0.0 (0.0–0.0)	20 (14–27)	0.0 (0.0–0.0)	0.1 (0.0–0.1)
Highincome	1,087,856	168 (124–222)	427 (327–543)	0.0 (0.0–0.0)	168 (124–221)	0.1 (0.1–0.1)	0.1 (0.1–0.2)
Latin America and Caribbean	601,551	23 (15–32)	48 (33–65)	0.0 (0.0–0.0)	23 (15–32)	0.0 (0.0–0.1)	0.1 (0.1–0.1)
North Africa and Middle East	631,727	77 (53–105)	117 (81–159)	0.0 (0.0–0.1)	77 (53–104)	0.2 (0.1–0.3)	0.3 (0.2–0.4)
South Asia	1,841,435	142 (95–199)	155 (105–221)	0.0 (0.0–0.0)	141 (94–198)	0.1 (0.1–0.2)	0.1 (0.1–0.2)
Sub-Saharan Africa	1,114,806	46 (32–62)	85 (59–115)	0.0 (0.0–0.0)	45 (32–62)	0.1 (0.1–0.2)	0.2 (0.1–0.2)

Table 3. Number of males and females with AMD MSVI, and the age-standardized prevalence (% [95% uncertainty intervals (UIs)]) of AMD MSVI (all ages and people aged ≥50 years) in 2020.

World Region	Total Population	Total number of AMD MSVI and aged-standardized AMD MSVI in 2020 (all ages)				Total number of AMD MSVI and aged-standardized AMD MSVI in people aged 50+ years in 2020			
		2020, total population ('000 s)	Number of males ('000 s) with AMD MSVI in 2020	Number of females ('000 s) with AMD MSVI in 2020	Age standardized prevalence of MSVI in males in 2020	Age standardized prevalence of MSVI in females in 2020	Number of females ('000 s) (50+ years) with AMD MSVI in 2020	Age standardized prevalence of MSVI in males in 2020	Age standardized prevalence of MSVI in females in 2020
Global	7,890,000	2747 (2207–3377)	3483 (2823–4236)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	2743 (2202–3371)	0.3 (0.3–0.4)	0.4 (0.3–0.4)
Southeast Asia, East Asia, and Oceania	2,192,710	1231 (982–1501)	1530 (1224–1865)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	1230 (981–1500)	0.4 (0.4–0.5)	0.5 (0.4–0.6)
Central Europe, Eastern Europe, and Central Asia	417,291	75 (60–94)	152 (121–188)	0.0 (0.0–0.0)	0.0 (0.0–0.1)	0.0 (0.0–0.1)	75 (60–94)	0.1 (0.1–0.2)	0.2 (0.1–0.2)
High-income	1,087,856	294 (232–363)	445 (350–554)	0.0 (0.0–0.0)	0.0 (0.0–0.0)	0.0 (0.0–0.0)	293 (232–362)	0.1 (0.1–0.2)	0.2 (0.1–0.2)
Latin America and Caribbean	601,551	137 (110–168)	196 (159–240)	0.1 (0.0–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	136 (109–168)	0.2 (0.2–0.3)	0.3 (0.2–0.3)
North Africa and Middle East	631,727	234 (185–295)	258 (204–320)	0.1 (0.1–0.1)	0.1 (0.1–0.2)	0.1 (0.1–0.2)	234 (185–295)	0.5 (0.4–0.7)	0.6 (0.5–0.7)
South Asia	1,841,435	571 (453–704)	649 (518–802)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	570 (452–703)	0.4 (0.3–0.5)	0.4 (0.4–0.5)
SubSaharan Africa	1,114,806	202 (160–253)	251 (198–313)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	0.1 (0.1–0.1)	202 (160–252)	0.5 (0.4–0.6)	0.5 (0.4–0.6)

Table 4. Percentage change in crude prevalence, number of people affected, and age-standardised prevalence of AMD blindness (presenting visual acuity <3/60) in adults age 50 years and older between 2000 and 2020 by world super region.

World Region	Crude Prevalence			Number of Cases ('000 s)			Age standardized prevalence		
	Male (%, 95% UI)	Female (%, 95% UI)	Both (%, 95% UI)	Male (%, 95% UI)	Female (%, 95% UI)	Both (%, 95% UI)	Male (%, 95% UI)	Female (%, 95% UI)	Both (%, 95% UI)
Global	-18.8 (-19.1 to -18.5)	-19.5 (-19.8 to -19.3)	-19.3 (-19.6 to -19.0)	43.3 (42.7 to 43.8)	41.4 (40.9 to 41.9)	42.1 (41.6 to 42.5)	-22.2 (-22.5 to -21.9)	-21.7 (-22.0 to -21.5)	-22.6 (-22.8 to -22.3)
High-income	3.9 (3.5 to 4.2)	-4.2 (-4.5 to -3.9)	-3.1 (-3.4 to -2.8)	52.8 (52.3 to 53.3)	33.5 (33.1 to 33.8)	38.4 (38.0 to 38.8)	-12.8 (-13.1 to -12.5)	-14.4 (-14.7 to -14.2)	-15.8 (-16.0 to -15.5)
Central Europe, Eastern Europe, and Central Asia	1.9 (1.5 to 2.3)	-10.0 (-10.4 to -9.7)	-6.9 (-7.3 to -6.6)	32.2 (31.7 to 32.7)	11.3 (10.9 to 11.8)	17.4 (17.0 to 17.9)	-5.0 (-5.3 to -4.6)	-15.1 (-15.4 to -14.7)	-12.7 (-13.0 to -12.3)
Latin America and Caribbean	-2.6 (-3.0 to -2.2)	2.5 (2.1 to 2.9)	1.3 (0.9 to 1.7)	92.0 (91.2 to 92.8)	109.9 (109.0 to 110.7)	103.6 (102.8 to 104.5)	-6.6 (-7.0 to -6.3)	-3.7 (-4.1 to -3.3)	-4.1 (-4.5 to -3.7)
North Africa and Middle East	-23.8 (-24.1 to -23.5)	-18.4 (-18.7 to -18.0)	-20.6 (-20.9 to -20.3)	58.4 (57.8 to 59.0)	69.9 (69.2 to 70.6)	65.1 (64.5 to 65.8)	-17.4 (-17.7 to -17.1)	-16.4 (-16.7 to -16.1)	-16.4 (-16.7 to -16.0)
South Asia	-28.3 (-28.7 to -28.0)	-32.7 (-32.9 to -32.4)	-30.5 (-30.8 to -30.2)	35.2 (34.7 to 35.8)	36.2 (35.6 to 36.8)	35.7 (35.1 to 36.3)	-28.5 (-28.8 to -28.2)	-34.1 (-34.4 to -33.9)	-31.4 (-31.7 to -31.1)
Southeast Asia, East Asia, and Oceania	-33.8 (-34.1 to -33.5)	-32.2 (-32.5 to -31.9)	-32.6 (-32.9 to -32.3)	30.9 (30.4 to 31.4)	38.3 (37.8 to 38.9)	35.5 (34.9 to 36.0)	-36.3 (-36.5 to -36.0)	-32.5 (-32.8 to -32.3)	-34.1 (-34.3 to -33.8)
Sub-Saharan Africa	-11.9 (-12.3 to -11.6)	-12.4 (-12.7 to -12.0)	-11.2 (-11.6 to -10.9)	55.8 (55.2 to 56.4)	70.0 (69.3 to 70.6)	64.7 (64.1 to 65.4)	-7.4 (-7.8 to -7.0)	-6.8 (-7.2 to -6.5)	-6.6 (-7.0 to -6.3)

Table 5. Percentage change in crude prevalence, number of people affected, and age-standardised prevalence of AMD MSVI (presenting visual acuity <6/18, ≥3/60) and in adults aged 50 years and older between 2000 and 2020 by world super region.

World Region	Crude Prevalence			Number of Cases ('000 s)			Age standardized prevalence		
	Male (%, 95% UI)	Female (%, 95% UI)	Both (%, 95% UI)	Male (%, 95% UI)	Female (%, 95% UI)	Both (%, 95% UI)	Male (%, 95% UI)	Female (%, 95% UI)	Both (%, 95% UI)
Global	9.8 (9.5 to 10.1)	10.3 (10.0 to 10.6)	10.1 (9.8 to 10.3)	93.7 (93.2 to 94.2)	93.8 (93.3 to 94.2)	93.7 (93.3 to 94.2)	6.5 (6.3 to 6.8)	10.5 (10.2 to 10.8)	8.7 (8.4 to 8.9)
High-income	12.9 (12.6 to 13.2)	2.1 (1.8 to 2.4)	5.6 (5.3 to 5.9)	66.1 (65.7 to 66.6)	42.2 (41.8 to 42.6)	50.8 (50.4 to 51.2)	-3.2 (-3.4 to -2.9)	-5.0 (-5.2 to -4.7)	-4.8 (-5.0 to -4.6)
Central Europe, Eastern Europe, and Central Asia	6.9 (6.6 to 7.2)	7.1 (6.8 to 7.4)	6.6 (6.3 to 6.9)	38.7 (38.3 to 39.1)	32.5 (32.2 to 32.9)	34.5 (34.2 to 34.9)	-0.0 (-0.3 to 0.2)	4.3 (4.0 to 4.6)	2.6 (2.4 to 2.9)
Latin America and Caribbean	3.7 (3.4 to 3.9)	7.8 (7.6 to 8.1)	6.3 (6.0 to 6.5)	104.3 (103.8 to 104.8)	120.7 (120.2 to 121.3)	113.7 (113.2 to 114.2)	0.0 (-0.2 to 0.3)	3.9 (3.7 to 4.2)	2.4 (2.1 to 2.6)
North Africa and Middle East	-11.9 (-12.2 to -11.7)	-6.7 (-7.0 to -6.5)	-9.3 (-9.5 to -9.0)	83.0 (82.5 to 83.5)	94.1 (93.6 to 94.6)	88.6 (88.1 to 89.1)	-4.6 (-4.8 to -4.3)	-3.2 (-3.4 to -2.9)	-3.8 (-4.1 to -3.6)
South Asia	5.8 (5.5 to 6.0)	2.1 (1.8 to 2.3)	4.0 (3.8 to 4.3)	99.6 (99.1 to 100.1)	106.4 (105.8 to 106.9)	103.1 (102.6 to 103.7)	0.4 (0.1 to 0.6)	-3.2 (-3.5 to -3.0)	-1.5 (-1.7 to -1.2)
Southeast Asia, East Asia, and Oceania	7.4 (7.2 to 7.7)	6.8 (6.5 to 7.0)	7.2 (6.9 to 7.5)	112.5 (111.9 to 113.0)	117.8 (117.2 to 118.3)	115.4 (114.8 to 115.9)	5.7 (5.4 to 5.9)	7.3 (7.0 to 7.5)	6.4 (6.2 to 6.7)
Sub-Saharan Africa	-8.4 (-8.7 to -8.2)	-0.5 (-0.8 to -0.2)	-4.2 (-4.4 to -3.9)	62.0 (61.6 to 62.4)	93.1 (92.5 to 93.6)	77.9 (77.4 to 78.3)	-2.5 (-2.7 to -2.3)	4.1 (3.8 to 4.4)	0.7 (0.5 to 1.0)

overcoming hurdles related to precise delivery methods, ensuring lasting benefits, and establishing safety protocols [23].

Strengths of the present study included the number of population-based data accessed and used, analysis of trends in the causes of blindness and MSVI, incorporation of nonlinear age trends and accounting for data that were not reported by age, and systematic quantitative analysis and reporting of uncertainty. Among the limitations of the present study, we can cite the shortage of data in some countries/regions and information on the burden of AMD in ethnic minorities, such as indigenous people. In some countries, population-based data were either collected sub nationally or more than a decade ago, and estimates may not represent the current reality of a given country. Also, most analysed studies used the Rapid Assessment of Cataract Surgical Services or RAAB methodologies, which may underestimate posterior pole diseases, such as AMD. The evolution of population-based studies, especially those employing advanced imaging technologies like fundus photography, should be elaborated to reflect how these methodologies can refine the accuracy of AMD prevalence studies [24].

Policymakers and the academic community should consider that AMD's social and economic impact is expected to increase substantially due to population growth and ageing [6]. Since population growth rates and life expectancies differ across regions, the burden of AMD will vary globally. Different from cataract and uncorrected refractive errors, the leading causes of blindness and vision impairment, respectively, the burden of AMD can only be alleviated if significant advances in research are made. Developing novel, cost-effective treatment modalities ideally restoring sight, and adopting a life course approach integrating all levels of care is paramount for managing AMD for the next decades.

SUMMARY

What was known before:

- Based on the Global Burden of Disease Study 2010, the Vision Loss Expert Group (VLEG) estimated that there were 2.1 million people blind due to macular diseases.

What this study adds:

- In 2020, 1.85 million (95%UI: 1.35 to 2.43 million) people were blind due to AMD, and another 6.23 million (95%UI: 5.04 to 7.58) presented with MSVI globally.
- From 2000 to 2020, there was a reduction in the crude prevalence of age-related macular degeneration (AMD)-related blindness globally and an increase in AMD-related moderate and severe vision impairment.

DATA AVAILABILITY

The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the coordinator of the Vision Loss Expert Group (Professor Rupert Bourne; rb@rupertbourne.co.uk) upon reasonable request. Data are located in controlled access data storage at Anglia Ruskin University.

REFERENCES

- Mitchell J, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. *The Lancet*. 2018;392:1147–59. [https://doi.org/10.1016/S0140-6736\(18\)31550-2](https://doi.org/10.1016/S0140-6736(18)31550-2)
- Rosenfeld PJ, et al. Ranibizumab for neovascular age-related macular degeneration. *N. Engl. J. Med.* 2006;355:1419–31.
- Bourne RRA, et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: An analysis for the Global Burden of Disease Study. *Lancet Glob. Heal.* 2021;9:e144–e160.
- Mitchell J, Bradley C. Quality of life in age-related macular degeneration: A review of the literature. *Health Q. Life Outcomes.* 2006;4:97.
- Eckert KA, Lansingh VC, Carter MJ & Frick KD Update of a Simple Model to Calculate the Annual Global Productivity Loss Due to Blindness and Moderate and Severe Vision Impairment. *Ophthalmic Epidemiol.* 2013;30.
- Burton MJ, et al. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. *Lancet Glob. Heal.* 2021;9:e489–e551.
- WHO. World report on vision. WHO; 2019 <https://www.who.int/publicatio%0D%0Ans/i/item/world-report-on-vision%0D%0A>.
- Keel S, et al. Strengthening the integration of eye care into the health system: Methodology for the development of the WHO package of eye care interventions. *BMJ Open Ophthalmol.* 2020;5:e000533.
- Bourne RRA, et al. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. *Lancet Glob. Heal.* 2017;5:e888–e897.
- Bourne RRA, et al. Trends in prevalence of blindness and distance and near vision impairment over 30 years: An analysis for the Global Burden of Disease Study. *Lancet Glob. Heal.* 2021;9:e130–e143.
- Flaxman SR, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. *Lancet Glob. Heal.* 2017;5:e1221–e1234.
- Zheng P, et al. Trimmed constrained mixed effects models: formulations and algorithms. *ArXiv190910700*. *Math Stat.* 2019. <http://arxiv.org/abs/1909.10700>.
- Vos T, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet.* 2020;396:1204–22.
- Vollset SE, et al. Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study. *Lancet.* 2020;396:1285–306.
- Muralikrishnan J, et al. Access to eye care during the COVID-19 pandemic, India. *Bull. World Health Organ.* 2022;100:135–43.
- Hong H, et al. The Challenge of Universal Eye Health in Latin America: Distributive inequality of ophthalmologists in 14 countries. *BMJ Open* 2016; 6.
- Heier JS, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. *Lancet.* 2023;402:1434–48.
- Chiang PPC, O'Connor PM, Le Mesurier RT, Keeffe JE. A global survey of low vision service provision. *Ophthalmic Epidemiol.* 2011;18:109–21.
- Austeng D, et al. Nurse-administered intravitreal injections of anti-VEGF: study protocol for noninferiority randomized controlled trial of safety, cost and patient satisfaction. *BMC Ophthalmol.* 2016;16:169.
- Bolme S, Austeng D, Morken TS, Follstad T, Halsteinli V. Cost consequences of task-shifting intravitreal injections from physicians to nurses in a tertiary hospital in Norway. *BMC Health Serv Res.* 2023;23:229 <https://doi.org/10.1186/s12913-023-09186-0>.
- Juncal VR, et al. Same-day bilateral intravitreal anti-vascular endothelial growth factor injections: Experience of a large Canadian retina center. *Ophthalmologica.* 2019;242:1–7. <https://doi.org/10.1159/000499115>.
- Borkar DS, et al. Endophthalmitis rates after bilateral same-day intravitreal anti-vascular endothelial growth factor injections. *Am J Ophthalmol.* 2018;194:1–6. <https://doi.org/10.1016/j.ajo.2018.06.022>.
- Kim K, et al. Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration. *Genome Res.* 2017;27:419–26.
- Mactaggart I, Limburg H, Bastawrous A, Burton MJ, Kuper H. Rapid assessment of avoidable blindness: Looking back, looking forward. *Br J Ophthalmol.* 2019;103:1549–52.

ACKNOWLEDGEMENTS

The Global Burden of Disease Study is primarily funded by the Bill & Melinda Gates Foundation (OPP1152504). The funder of this study had no role in the study design, data collection, data analysis, data interpretation, or writing of the publication.

AUTHOR CONTRIBUTIONS

Please see Appendix for more detailed information about individual author contributions to the research, divided into the following categories: managing the overall research enterprise; writing the first draft of the manuscript; primary responsibility for applying analytical methods to produce estimates; primary responsibility for seeking, cataloguing, extracting, or cleaning data; designing or coding figures and tables; providing data or critical feedback on data sources; developing methods or computational machinery; providing critical feedback on methods or results; drafting the manuscript or revising it critically for important intellectual content; and managing the estimation or publications process.

FUNDING

This study was funded by Brien Holden Vision Institute, Fondation Thea, Fred Hollows Foundation, Bill & Melinda Gates Foundation, Lions Clubs International Foundation (LCIF), Sightsavers International, and University of Heidelberg.

COMPETING INTERESTS

GBD 2019 Blindness and Vision Impairment Collaborators T W Bärnighausen reports support for the present manuscript from Fondation Botnar and Harvard T.H. Chan School of Public Health; grants or contracts from National Institutes of Health (NIH), Wellcome, German National Science Foundation, German Ministry of Education and Research, Volkswagen Foundation, European Union Horizon Europe, German Ministry of the Environment, Alexander von Humboldt Foundation, Else-Kröner Fresenius Foundation, International Vaccine Institute for grants to Heidelberg Institute of Global Health, Heidelberg University, Germany; stock or stock options in EUR 5000 ownership stake in a consultancy on climate change and health research; all outside the submitted work. R Bai reports support for the present manuscript from Social Science Fund of Jiangsu Province (grant number 21GLD008) N Bayleyegn reports leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid with project HIPPO and GECKO as a hospital lead as well as Ethiopia as a member of a surgical society. S Bhaskar reports grants or contracts from Japan Society for the Promotion of Science (JSPS) Grant 2023-25 and Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. T Braithwaite reports grants or contracts from Fight for Sight/Royal College of Ophthalmologists for Zakarian Award (RCOZAK2202). X Dai reports support for the present manuscript from IHME/UW for paid salary. A Dastiridou support for attending meetings and/or travel from THEA and ABBVIE. M Foschi reports consulting fees from Roche and Novartis as a scientific consultant; support for attending meetings and/or travel from Roche, Novartis, Biogen, Merck, and Sanofi; leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid with MSBase collaboration scientific leadership group as a member. J M Furtado reports consulting fees from Pan American Health Organization and Lions Club International Foundation. S Hallaj reports grants or contracts from National Institute of Health Bridge to Artificial Intelligence common fund, grant # OT2OD032644. I M Karaye support for attending meetings and/or travel from Hofstra University and National Academies of Sciences, Engineering, and Medicine. K Krishan reports other support from Kewal Krishan acknowledges non-financial support from the UGC Centre of Advanced Study, CAS II, awarded to the Department of Anthropology, Panjab University, Chandigarh, India, outside the submitted work. T Laksono reports support for attending meetings and/or travel outside the submitted work. V C Lansingh reports support for attending meetings and/or travel from HwelpMeSee. M Lee reports support from the Ministry of Education of the Republic of Korea and the National Research Foundation of Korea (NRF-2021R111A4A01057428) and Bio-convergence Technology Education Program through the Korea Institute for Advancement Technology (KIAT) funded by the Ministry of Trade, Industry and Energy (No. P0017805), all outside the submitted work. C McAlinden reports grants or contracts from the Welsh Government for a research grant related to diabetic eye disease (unpaid role); consulting fees from: Acufocus (Irvine, California, USA), Atia Vision (Campbell, California, USA), Bausch and Lomb (Bridgewater, New Jersey, USA), BVI (Liège, Belgium), Coopervision (Pleasanton, California, USA), Cutting Edge (Labège, France), Fudan University (Fudan, China), Hoya (Frankfurt, Germany), Knowledge Gate Group (Copenhagen, Denmark), Johnson & Johnson Surgical Vision (Santa Ana, California, USA), Keio University (Tokyo, Japan), Ludwig-Maximilians-University (München, Germany), Medevise Consulting SAS (Strasbourg, France), Ophtec BV (Groningen, The Netherlands), SightGlass vision (Menlo Park, California, USA), Science in Vision (Bend, Oregon, USA), Scope (Crawley, UK), SpyGlass (Aliso Viejo, California, USA), Sun Yat-sen University (Guangzhou, China), Targomed GmbH (Bruchsal, Germany), University of São Paulo (São Paulo, Brazil), Vold Vision (Arkansas, USA); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Scope (Crawley, UK), and Thea pharmaceuticals (Clemont-Ferrand, France); support for attending meetings and/or travel from the following over the past thirty-six months: Bayer (Leverkusen, Germany), British Society of Refractive Surgery (Oxford, UK), Portuguese Society of Ophthalmology (Coimbra, Portugal), Royal College of Ophthalmologists (London, UK), Scope (Crawley, UK), Thea pharmaceuticals (Clemont-Ferrand, France); leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid with the British Society for Refractive Surgery as a council member (unpaid role), a PROM advisor to the Royal College of Ophthalmologists (unpaid role), an editorial board member for Graefes Archive for Clinical and Experimental Ophthalmology, Eye and Vision, Archives of Medical Science, Journal of Clinical Medicine, Journal of Ophthalmology, and Journal of Clinical and Experimental Ophthalmology as well as an Associate Editor for Frontiers in Medicine – Ophthalmology; and other support as a developer of the Quality of Vision (QoV) questionnaire and the Orthokeratology and Contact Lens Quality of Life Questionnaire (OCL-QoL) having a financial interest in these tools and consults on topics including Rasch analysis, questionnaires, statistical analyses, and clinical/

surgical ophthalmology topics. Dr McAlinden has undertaken paid peer reviews for Research Square (Durham, North Carolina, USA); all outside the submitted work. Y L Samodra reports grants or contracts from Taipei Medical University for a Ph.D. Scholarship; leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid with Benang Merah Research Center as Co-founder, all outside the submitted work. J A Singh reports consulting fees from AstraZeneca, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, MediQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, and Practice Point communications; and the National Institutes of Health and the American College of Rheumatology; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the speaker's bureau of Simply Speaking; support for attending meetings and/or travel from OMERACT as a past steering committee for attending their meeting every 2 years; participation on a Data Safety Monitoring Board or Advisory Board with FDA Arthritis Advisory Committee as a member (No financial support); leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid as a past steering committee member of the OMERACT, an international organization that develops measures for clinical trials and receives arm's length funding from 12 pharmaceutical companies, Co-Chair of the Veterans Affairs Rheumatology Field Advisory Committee (No financial support), and editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis (No financial support); stock or stock options in Atai life sciences, Kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix Pharmaceuticals Holding Corp., and Charlotte's Web Holdings, Inc. as well as previous stock options in Amarin, Viking and Moderna pharmaceuticals, all outside the submitted work. E Skiadaresi reports consulting fees from Bayer (Leverkusen, Germany), Novartis (Basel, Switzerland), Roche (Basel, Switzerland), Medevise Consulting SAS (Strasbourg, France); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bayer (Leverkusen, Germany), Novartis (Basel, Switzerland), and Roche (Basel, Switzerland); support for attending meetings and/or travel from Bayer (Leverkusen, Germany), Novartis (Basel, Switzerland), and Roche (Basel, Switzerland); leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid with Chair of ATHENA Trial Steering Committee, UK (unpaid); all outside the submitted work. B T Taye reports support for the present manuscript from Brien Holden Vision Institute, Fondation Thea, Fred Hollows Foundation, Bill & Melinda Gates Foundation, Lions Clubs International Foundation (LCIF), Sightsavers International, and University of Heidelberg. The funder has no role in designing and preparing the manuscript. J H V Ticoalu leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid with Benang Merah Research Center as Co-founder. M Zielińska reports other support as an AstraZeneca employee; outside the submitted work. **Vision Loss Expert Group of the Global Burden of Disease Study** T Braithwaite reports grants or contracts from any entity from Zakarian Award Fight for Sight/Royal College of Ophthalmologists (RCOZAK2202). A Bron reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Thea. N Congdon reports grants or contracts from any entity from Welcome Trust and MRC; consulting fees from Belkin Vision; and support for attending meetings and/or travel from Singapore National Eye Center. M A Del Monte reports support for attending meetings and/or travel from the University of Michigan; and leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid as past president of Costenbader Society. T Fricke reports grants or contracts from any entity from Brien Holden Vision Institute, Victorian Lions Foundation, International Myopia Institute, and Australian government; and support for attending meetings and/or travel from International Myopia Institute. D Friedman reports grants or contracts from any entity from Perivision and Genentech (to the institution for research); consulting fees from Abbvie and Life Biosciences; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Thea Pharmaceuticals; support for attending meetings and/or travel from Thea Pharmaceuticals; and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, from Orbis International as member of board of governors. J M Furtado reports consulting fees from Pan American Health Organization and from Lions Club International Foundation. G Gazzard reports consulting fees from Alcon Laboratories, Inc; Allergan, Inc; BELKIN Vision LTD; Carl Zeiss Meditec; Elios; Genentech/Roche; Reichert; Théa and ViaLase; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Alcon Laboratories, Inc; BELKIN Vision Ltd; Carl Zeiss Meditec; Elios and Ellex; participation on a Data Safety Monitoring Board or Advisory Board with Alcon Laboratories, Inc; Allergan, Inc; BELKIN Vision Ltd; Carl Zeiss Meditec; Elios and Visufarma; and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid with Glaucoma UK Medical Advisory Board and UK&Eire Glaucoma Society as president. M E Hartnett reports support for the present manuscript (e.g., funding, provision of study materials,

medical writing, article processing charges, etc.) from Michael F. Marmor, M.D. Professor of Retinal Science and Disease as endowment to support salary; grants or contracts from any entity (from National Eye Institute R01 EY017011 and National Eye Institute R01 EY015130) as partial salary support; patents planned, issued or pending (WO2015123561A2 and WO2021062169A1); and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid with Jack McGovern Coats' Disease Foundation and as director of Women's Eye Health and Macular Society Grant Review Chair. J H Kempen reports support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) from Mass Eye and Ear Global Surgery Program (as support of salary); and grants or contracts from any entity from Sight for Souls (as support of salary). J E Kim reports consulting fees from Genentech/Roche, DORC, Notal Vision and Outlook Therapeutics (all as payment to J E Kim); participation on a Data Safety Monitoring Board or Advisory Board with Allergan, Amgen, Apellis, Bausch&Lomb, Clearside, Coherus, Novartis and Regeneron (all as participation on advisory board); leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with AAO, APRIS, ASRS, Macular Society and NAEVR/AEVR (all unpaid); and receipt of equipment, materials, drugs, medical writing, gifts or other services from Clearside and Genentech/Roche (both for medical writing). V C Lansingh reports consulting fees from HelpMeSee (as an employee); and support for attending meetings and/or travel from HelpMeSee (pay airfare and hotel). J Leasher reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid with National Eye Institute (as a member) and National Eye Health Education Program planning committee (unpaid). M Nowak reports participation on a Data Safety Monitoring Board or Advisory Board with Vision Express Co. Poland as the chairman of medical advisory board of Vision Express Co. Poland. P Ramulu reports grants or contracts from National Institute of Health and Perfuse Therapeutics; and consulting fees from Alcon and W. L. Gore. F Topouzis reports grants or contracts from Théa, Omikron, Pfizer, Alcon, Abbvie and Bayer (all paid to Institution); consulting fees from Omikron, Théa and Bausch & Lomb (all paid to Topouzis); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Omikron (paid to Topouzis), Abbvie and Roche (both paid to Institution); and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid with European Glaucoma

Society (as president), Greek Glaucoma Society (as president) and Board of Governors, World Glaucoma Association (all unpaid).

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41433-024-03050-z>.

Correspondence and requests for materials should be addressed to João M. Furtado.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

VISION LOSS EXPERT GROUP OF THE GLOBAL BURDEN OF DISEASE STUDY

João M. Furtado^{1,✉}, Jost B. Jonas², Ian Tapply³, Arthur G. Fernandes^{4,5}, Maria Vittoria Cicinelli^{6,7}, Alessandro Arrigo⁸, Nicolas Leveziel^{9,10}, Serge Resnikoff^{11,12}, Hugh R. Taylor¹³, Tabassom Sedighi¹⁴, Seth Flaxman¹⁵, Maurizio Battaglia Parodi¹⁶, Mukkharrem M. Bikbov¹⁷, Tasanee Braithwaite^{18,19}, Alain Bron²⁰, Ching-Yu Cheng^{21,22}, Nathan Congdon^{23,24,25}, Monte A. Del Monte^{26,27}, Joshua R. Ehrlich^{28,29}, Tim Fricke^{30,31,32}, David Friedman³³, Gus Gazzard³⁴, M. Elizabeth Hartnett³⁵, Rim Kahloun³⁶, John H. Kempen^{37,38,39,40}, Moncef Khairallah⁴¹, Rohit C. Khanna^{42,43,44,45}, Judy E. Kim⁴⁶, Van Charles Lansingh^{47,48,49}, Janet Leasher⁵⁰, Kovin S. Naidoo^{44,51}, Vinay Nangia⁵², Michal Nowak⁵³, Konrad Pesudovs⁵⁴, Tunde Peto⁵⁵, Pradeep Ramulu⁵⁶, Fotis Topouzis⁵⁷, Mitiadis Tsilimbaris⁵⁸, Ya Xing Wang⁵⁹, Ningli Wang⁶⁰ and Rupert R. A. Bourne¹⁴

¹Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil. ²Department of Ophthalmology, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany. ³Department of Ophthalmology, Cambridge University Hospitals, Cambridge, UK. ⁴Federal University of São Paulo, São Paulo, SP, Brazil. ⁵University of Calgary, Calgary, AB, Canada. ⁶School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. ⁷Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy. ⁸Scientific Institute San Raffaele Hospital, Vita-Salute University, Milan, Italy. ⁹University of Poitiers, Poitiers, France. ¹⁰CHU de Poitiers, Poitiers, France. ¹¹Brien Holden Vision Institute, Sydney, NSW, Australia. ¹²School of Optometry and Vision Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. ¹³School of Population and Global Health, University of Melbourne, Carlton, VIC, Australia. ¹⁴Vision and Eye Research Institute, Anglia Ruskin University, Cambridge, UK. ¹⁵Department of Computer Science, University of Oxford, Oxford, UK. ¹⁶Department of Ophthalmology, Vita-Salute San Raffaele University, Milano, Italy. ¹⁷Ufa Eye Research Institute, Ufa, Russia. ¹⁸School of Life Course and Population Sciences, King's College London, London, UK. ¹⁹The Medical Eye Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK. ²⁰University Hospital, Dijon, France. ²¹National University of Singapore, Singapore, Singapore. ²²Singapore Eye Research Institute, Singapore, Singapore. ²³Queen's University Belfast, Northern Ireland, Belfast, UK. ²⁴Orbis International, New York, USA. ²⁵Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China. ²⁶University of Michigan, Ann Arbor, USA. ²⁷Kellogg Eye Center, Ann Arbor, USA. ²⁸Institute for Social Research, University of Michigan, Ann Arbor, USA. ²⁹Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, USA. ³⁰Australian College of Optometry, Melbourne, Vic, Australia. ³¹University of Melbourne, Melbourne, Vic, Australia. ³²UNSW Sydney, Sydney, NSW, Australia. ³³Mass Eye and Ear, Harvard Medical School, Boston, USA. ³⁴Institute of Ophthalmology UCL & NIHR Biomedical Research Centre, London, UK. ³⁵Stanford University, Stanford, USA. ³⁶Associated Ophthalmologists of Monastir, Monastir, Tunisia. ³⁷Department of Ophthalmology, Harvard University, Boston, MA, USA. ³⁸Eye Unit, MyungSung Medical College, Addis Ababa, Ethiopia. ³⁹Department of Ophthalmology, Addis Ababa University, Addis Ababa, Ethiopia. ⁴⁰Sight for Souls, Bellevue, WA, USA. ⁴¹Fattouma Bourguiba University Hospital, University of Monastir, Monastir, Tunisia. ⁴²Allen Foster Community Eye Health Research Centre, Gullapalli Pratibha Rao International Centre for Advancement of Rural Eye Care, L.V. Prasad Eye Institute, Hyderabad, India. ⁴³Brien Holden Eye Research Centre, L.V. Prasad Eye Institute, Banjara Hills, Hyderabad, India. ⁴⁴School of Optometry and Vision Science, University of New South Wales, Sydney, Australia. ⁴⁵University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA. ⁴⁶University of Texas Southwestern Medical Center, Dallas, USA. ⁴⁷HelpMeSee, Instituto Mexicano de Oftalmología, New York, USA. ⁴⁸University of Miami, Coral Gables, USA. ⁴⁹University of Utah, Salt Lake City, USA. ⁵⁰Nova Southeastern University College for Optometry, Fort Lauderdale, Florida, USA. ⁵¹African Vision Research Institute, University of KwaZulu-Natal (UKZN), Durban, South Africa. ⁵²Suraj Eye Institute, 559, New colony, Nagpur, India. ⁵³Institute of Optics and Optometry, University of Social Science, 121 Gdanska str, Lodz, 90-519, Poland. ⁵⁴Medicine & Health, University of New South Wales, Sydney, NSW, Australia. ⁵⁵Centre for Public Health, Queens University Belfast, Northern Ireland, Belfast, UK. ⁵⁶John Hopkins Wilmer Eye Institute, Baltimore, USA. ⁵⁷1st Department of Ophthalmology, Medical School, Aristotle University of Thessaloniki, Ahepa Hospital, Thessaloniki, Greece. ⁵⁸University of Crete Medical School, Gíofrakia, Greece. ⁵⁹Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing, China. ⁶⁰Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China

THE GBD 2019 BLINDNESS AND VISION IMPAIRMENT COLLABORATORS

João M. Furtado⁶¹, Jost B. Jonas^{62,63}, Ian Tapp³, Arthur G. Fernandes⁶⁴, Maria Vittoria Cicinelli⁶⁵, Alessandro Arrigo⁸, Nicolas Levezuel^{66,67}, Paul Svitil Briant⁶⁸, Theo Vos^{68,69}, Serge Resnikoff^{11,70}, Hugh R. Taylor¹³, Tabassom Sedighi¹⁴, Florian Fischer⁷¹, Yohannes Habtegiorgis Abate⁷², Mohammad Abdollahi^{73,74}, Tadele Girum Girum Adal⁷⁵, Isaac Yeboah Addo^{76,77}, Kishor Adhikari^{78,79}, Prerna Agarwal⁸⁰, Antonella Agodi⁸¹, Williams Agyemang-Duah⁸², Aqeel Ahmad⁸³, Hamid Ahmadi^{84,85}, Hooman Ahmadvazadeh⁸⁶, Fares Alahdab⁸⁷, Ahmad Samir Alfaar^{88,89}, Robert Kaba Alhassan⁹⁰, Syed Shujait Shujait Ali⁹¹, Louay Almidani^{92,93}, Sofia Androudi⁹⁴, Abhishek Anil^{95,96}, Anayochukwu Edward Anyasodor⁹⁷, Jalal Arabloo⁹⁸, Mubarek Yesse Ashemo^{99,100}, Seyyed Shamsadin Athari¹⁰¹, Desta Debalkie Atnafu¹⁰², Alok Atreya¹⁰³, Melese Kitu Ayalew^{104,105}, Yared Asmare Aynalem^{106,107}, Zewdu Bishaw Aynalem¹⁰⁸, Ahmed Y. Azzam^{109,110}, Sara Bagherieh¹¹¹, Ruhai Bai¹¹², Martina Barchitta¹¹³, Mainak Bardhan¹¹⁴, Till Winfried Bärnighausen^{115,116}, Maurizio Battaglia Parodi¹¹⁶, Nebiyu Simegnew Bayileegn¹¹⁷, Fatemeh Bazvand¹¹⁸, Ahmet Begde^{119,120}, Babak Behnam^{121,122}, Akshaya Srikanth Bhagavathula¹²³, Sonu Bhaskar^{124,125}, Gurjit Kaur Bhatti¹²⁶, Jasvinder Singh Bhatti¹²⁷, Bagas Suryo Bintoro^{128,129}, Marina G. Birck^{130,131}, Tasanee Braithwaite^{132,133}, Katrin Burkart^{68,69}, Yasser Bustanji^{134,135}, Florentino L. Caetano dos Santos¹³⁶, Vera L. A. Carneiro^{137,138}, Muthia Cenderadewi^{139,140}, Vijay Kumar Chattu^{141,142}, Dinh-Toi Chu¹⁴³, Kaleb Coberly⁶⁸, Natália Cruz-Martins^{144,145}, Omid Dadras^{146,147}, Xiaochen Dai^{68,69}, Ana Maria Dascalu^{148,149}, Mohsen Dashti¹⁵⁰, Anna Dastiridou^{151,152}, Maedeh Dastmardi^{153,154}, Xinlei Deng¹⁵⁵, Nikolaos Dervenis^{156,157}, Vioth Gnana Chellaiyan Devanbu¹⁵⁸, Mengistie Diress¹⁵⁹, Shirin Djalalinia¹⁶⁰, Joshua R. Ehrlich^{161,162}, Michael Ekholuenetale^{163,164}, Temitope Cyrus Ekundayo¹⁶⁵, Iman El Sayed¹⁶⁶, Muhammed Elhadi¹⁶⁷, Mehdi Emamverdi¹⁶⁸, Ambaw Abebaw Emrie¹⁶⁹, Adeniyi Francis Fagbamigbe^{163,170}, Ayesha Fahim¹⁷¹, Umar Farooq¹⁷², Hossein Farrokhpour^{173,174}, Ali Fatehizadeh¹⁷⁵, Alireza Feizkhah¹⁷⁶, Lorenzo Ferro Desideri¹⁷⁷, Getahun Fetensa¹⁷⁸, Bikila Regassa Feyisa¹⁷⁹, Seth Flaxman¹⁸⁰, Ali Forouhari^{181,182}, Matteo Foschi^{183,184}, Kayode Raphael Fowobaje^{163,185}, Aravind P. Gandhi¹⁸⁶, Tilaye Gebru Gebi¹⁸⁷, Miglas W. Gebregergis¹⁸⁸, Mesfin Gebrehiwot¹⁸⁹, Brhane Gebremariam^{190,191}, Gebreamlak Gebremedhn Gebremeskel^{192,193}, Yibeltal Yismaw Gela¹⁵⁹, Molalegn Mesele Gesese¹⁹⁴, Khalil Ghasemi Falavarjani¹⁹⁵, Fariba Ghassemi¹⁹⁶, Sherief Ghazy¹⁹⁷, Mahaveer Golechha¹⁹⁸, Pouya Goleij^{199,200}, Sapna Gupta²⁰¹, Veer Bala Gupta²⁰², Vivek Kumar Gupta²⁰³, Teklehaimanot Gereziher Haile¹⁹², Semira Goitum Hailu²⁰⁴, Arvin Haj-Mirzaian^{205,206}, Aram Halimi²⁰⁷, Shahin Hallaj^{208,209}, Billy Randall Hammond²¹⁰, Ikramul Hasan²¹¹, Hamidreza Hasani²¹², Hossein Hassanian-Moghaddam^{213,214}, Mahsa Heidari-Foroozan^{215,216}, Sung Hwi Hong^{217,218}, Praveen Hoogar²¹⁹, Mehdi Hosseinzadeh^{220,221}, Chengxi Hu²²², Hong-Han Huynh²²³, Mustapha Immurana⁹⁰, Chidozie C. D. Iwu²²⁴, Louis Jacob^{225,226}, Abdollah Jafarzadeh^{227,228}, Mihajlo Jakovljevic^{229,230}, Shubha Jayaram²³¹, Mohammad Jokar^{232,233}, Nitin Joseph²³⁴, Charity Ehimwenma Joshua²³⁵, Gebisa Guyasa Kabito²³⁶, Laleh R. Kalankesh²³⁷, Sagarika Kamath²³⁸, Himal Kandel^{239,240}, Ibraheem M. Karaye^{241,242}, Hengameh Kasraei^{195,243}, Gbenga A. Kayode^{244,245}, Shemsu Kedir²⁴⁶, Yousef Saleh Khader²⁴⁷, Himanshu Khajuria²⁴⁸, Moawiah Mohammad Khatatbeh²⁴⁹, Mahalaqua Nazli Khatib²⁵⁰, Zahra Khorrami²⁵¹, Yun Jin Kim²⁵², Adnan Kisa^{253,254}, Sezer Kisa²⁵⁵, Soewarta Kosen²⁵⁶, Ai Koyanagi²⁵⁷, Kewal Krishan²⁵⁸, Chandrakant Lahariya^{259,260}, Tri Laksono^{261,262}, Dharmesh Kumar Lal²⁶³, Van Charles Lansingh^{264,265}, Trang D. T. Le^{266,267}, Janet L. Leasher²⁶⁸, Munjae Lee²⁶⁹, Seung Won Lee²⁷⁰, Wei-Chen Lee²⁷¹, Stephen S. Lim^{68,69}, Xuefeng Liu^{272,273}, Alireza Mahmoudi²⁷⁴, Razzagh Mahmoudi²⁷⁵, Kashish Malhotra²⁷⁶, Vahid Mansouri²⁷⁷, Roy Rillera Marzo^{278,279}, Andrea Maugeri¹¹³, Colm McAlinden^{280,281}, Tesfahun Mekene Meto²⁸², Abera M. Mersha²⁸³, Tomislav Mestrovic^{68,284}, Ephrem Tesfaye Mihretie²⁸⁵, Mehdi Mirzaei²⁸⁶, Prasanna Mithra²³⁴, Nouh Saad Mohamed^{287,288}, Soheil Mohammadi¹⁷³, Abdulwase Mohammed²⁸⁹, Ali H. Mokdad^{68,69}, Hossein Molavi Vardanjani²⁹⁰, Mohammad Ali Moni²⁹¹, Fateme Montazeri^{216,292}, Maryam Moradi²⁹³, Parsa Mousavi²⁹⁴, Ahmed Nuru Muhamed¹⁶⁹, Admir Mulita²⁹⁵, Kovin S. Naidoo^{70,296}, Ganesh R. Naik^{297,298}, Shumaila Nargus²⁹⁹, Zuhair S. Natto^{300,301}, Biswa Prakash Nayak²⁴⁸, Mohammad Negaresh^{302,303}, Hadush Negash³⁰⁴, Seyed Aria Nejadghaderi^{215,216}, Dang H. Nguyen^{305,306}, Hien Quang Nguyen³⁰⁷, Phat Tuan Nguyen³⁰⁸, Van Thanh Nguyen³⁰⁹, Robina Khan Niazi³¹⁰, Mamoona Noreen³¹¹, Ogochukwu Janet Nzopotum^{312,313}, Ismail A. Odetokun³¹⁴, Andrew T. Olagunju^{315,316}, Matthew Idowu Olatubi³¹⁷, Obinna E. Onwujekwe³¹⁸, Michal Ordak³¹⁹, Uchechukwu Levi Osuagwu^{320,321}, Nikita Otsavnov³²², Mayowa O. Owolabi^{323,324}, Jagadish Rao Padubidri³²⁵, Parsa Panahi³²⁶, Ashok Pandey^{327,328}, Shahina Pardhan¹⁴, Jay Patel^{329,330}, Venkata Suresh Patthipati^{331,332}, Shrikant Pawar³³³, Arokiasamy Perianayagam³³⁴, Ionela-Roxana Petcu³³⁵, Hoang Tran Pham³³⁶, Ibrahim Qattea³³⁷, Pankaja Raghav Raghav³³⁸, Fakher Rahim^{339,340}, Vafa Rahimi-Movaghar³⁴¹, Mohammad Hifz Ur Rahman³⁴², Mosiur Rahman³⁴³, Premkumar Ramasubramani³⁴⁴, Ahmed Mustafa Rashid³⁴⁵, Annisa Utami Rauf³⁴⁶, Elrashdy Moustafa Mohamed Redwan^{347,348}, Nazila Rezaei²⁹², Priyanka Roy³⁴⁹, Zahra Saadatian^{350,351}, Siamak Sabour³⁵², Basema Saddik³⁵³, Umar Saeed^{354,355}, Sare Safi^{84,356}, Sher Zaman Safi^{357,358}, Amene Saghadzadeh³⁵⁹, Fatemeh Saheb Sharif-Askari³⁶⁰, Narjes Saheb Sharif-Askari³⁶¹, Amirhossein Sahebkar^{362,363}, Joseph W. Sakshaug^{364,365}, Saina Salahi³⁶⁶, Sarvenaz Salahi^{367,368}, Mohamed A. Saleh^{353,369}, Yoseph Leonardo Samodra³⁷⁰, Vijaya Paul Samuel³⁷¹, Abdallah M. Samy^{372,373}, Aswini Saravanan^{374,375}, Monika Sawhney³⁷⁶, Mete Saylan³⁷⁷, Sayed Mansoor Sediqi^{378,379}, Siddharthan Selvaraj³⁸⁰, Yashendra Sethi³⁸¹, Allen Seylani³⁸², Jaffer Shah³⁸³, Samiah Shahid^{384,385}, Moyad Jamal Shahwan³⁸⁶, Masood Ali Shaikh³⁸⁷, Muhammad Aaqib Shamim⁹⁵, Maryam Shayan^{388,389}, Mika Shigematsu³⁹⁰, Aminu Shittu³⁹¹, Seyed Afshin Shorofi^{392,393}, Emmanuel Edwar Siddig^{394,395}, Juan Carlos Silva³⁹⁶, Jasvinder A. Singh^{397,398}, Paramdeep Singh³⁹⁹, Eirini Skiadaresi⁴⁰⁰, Raúl A. R. C. Sousa⁴⁰¹, Chandrashekhar T. Sreeramareddy⁴⁰², Vladimir I. Starodubov⁴⁰³, Birhan Tsegaw Taye⁴⁰⁴, Jansje Henny Vera Ticoalu⁴⁰⁵, Guesh Mebrahtom Tsegay¹⁹², Miltiadis K. Tsilimbaris⁴⁰⁶, Saif Ullah⁴⁰⁷, Muhammad Umair^{408,409}, Sahel Valadan Tahbaz^{410,411}, Nuwan Darshana Wickramasinghe⁴¹², Guadie Sharew Wondimagegn^{413,414}, Lin Yang^{415,416}, Arzu Yigit⁴¹⁷, Dong Keon Yon⁴¹⁸, Naohiro Yonemoto^{419,420}, Yuyi You^{239,421}, Mikhail Sergeevich Zastrozhin^{422,423}, Hanqing Zhao⁴²⁴, Peng Zheng^{68,69}, Makan Ziafati⁴²⁵, Magdalena Zielińska⁴²⁶, Jaimie D. Steinmetz^{68,427} and Rupert R. A. Bourne^{14,427}

- ⁶¹Division of Ophthalmology, University of São Paulo, Ribeirão Preto, Brazil. ⁶²Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland. ⁶³Department of Ophthalmology, Heidelberg University, Mannheim, Germany. ⁶⁴Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, São Paulo, Brazil. ⁶⁵Department of Ophthalmology, San Raffaele Scientific Institute, Milano, Italy. ⁶⁶Ophthalmology Department, CHU de Poitiers (Poitiers University Hospital), Poitiers, France. ⁶⁷National Institute of Health and Medical Research (INSERM), Poitiers, France. ⁶⁸Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. ⁶⁹Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA. ⁷⁰School of Optometry and Vision Science, University of New South Wales, Sydney, NSW, Australia. ⁷¹Institute of Public Health, Charité Universitätsmedizin Berlin (Charité Medical University Berlin), Berlin, Germany. ⁷²Department of Clinical Governance and Quality Improvement, Aleta Wondo Hospital, Aleta Wondo, Ethiopia. ⁷³The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran. ⁷⁴School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. ⁷⁵Department of Public Health, Wolkite University, Wolkite, Ethiopia. ⁷⁶Centre for Social Research in Health, University of New South Wales, Sydney, NSW, Australia. ⁷⁷Quality and Systems Performance Unit, Cancer Institute NSW, Sydney, NSW, Australia. ⁷⁸School of Public Health & Dept. of Community Medicine, Chitwan Medical College & Teaching Hospital, Bharatpur, Nepal. ⁷⁹Public Health Section, Himalayan Environment and Public Health Network (HEPHN), Chitwan, Nepal. ⁸⁰Department of Physiology, Government Institute of Medical Sciences, Greater Noida, India. ⁸¹Department of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania, Catania, Italy. ⁸²Department of Geography and Planning, Queen's University, Kingston, ON, Canada. ⁸³Department of Medical Biochemistry, Shaqra University, Shaqra, Saudi Arabia. ⁸⁴Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁸⁵Department of Ophthalmology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁸⁶Bascom Palmer Eye Institute, University of Miami, Miami, FL, USA. ⁸⁷Evidence-Based Practice Center, Mayo Clinic Foundation for Medical Education and Research, Rochester, MN, USA. ⁸⁸Department of Ophthalmology, University of Leipzig Medical Center, Leipzig, Germany. ⁸⁹Department of Ophthalmology, Charité Medical University Berlin, Berlin, Germany. ⁹⁰Institute of Health Research, University of Health and Allied Sciences, Ho, Ghana. ⁹¹Center for Biotechnology and Microbiology, University of Swat, Swat, Pakistan. ⁹²Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ⁹³Doheny Image Reading and Research Lab (DIRRL) - Doheny Eye Institute, University of California Los Angeles, Los Angeles, CA, USA. ⁹⁴Department of Medicine, University of Thessaly, Volos, Greece. ⁹⁵Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India. ⁹⁶All India Institute of Medical Sciences, Bhubaneswar, India. ⁹⁷School of Dentistry and Medical Sciences, Charles Sturt University, Orange, NSW, Australia. ⁹⁸Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. ⁹⁹Department of Public Health, Jimma University, Jimma, Ethiopia. ¹⁰⁰Department of Public Health, Wachemo University, Hossana, Ethiopia. ¹⁰¹Department of Immunology, Zanjan University of Medical Sciences, Zanjan, Iran. ¹⁰²Department of Health System and Health Economics, Bahir Dar University, Bahir Dar, Ethiopia. ¹⁰³Department of Forensic Medicine, Lumbini Medical College, Palpa, Nepal. ¹⁰⁴Epidemiology, Eyu-Ethiopia, Bahir dar, Ethiopia. ¹⁰⁵College of Medicine and Health Sciences, Bahir Dar University, Bahir dar, Ethiopia. ¹⁰⁶Department of Nursing, Debre Berhan University, Debre Berhan, Ethiopia. ¹⁰⁷Department of Nursing, University of Alberta, Edmonton, AB, Canada. ¹⁰⁸Department of Nursing, Injibara University, Injibara, Ethiopia. ¹⁰⁹Department of Neurovascular Research, Nested Knowledge, Inc, Saint Paul, MN, USA. ¹¹⁰Faculty of Medicine, October 6 University, 6th of October City, Egypt. ¹¹¹School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. ¹¹²School of Public Affairs, Nanjing University of Science and Technology, Nanjing, China. ¹¹³Department of Medical and Surgical Sciences and Advanced Technologies "GF Ingrassia", University of Catania, Catania, Italy. ¹¹⁴Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA. ¹¹⁵Heidelberg Institute of Global Health (HIGH), Heidelberg University, Heidelberg, Germany. ¹¹⁶T.H. Chan School of Public Health, Harvard University, Boston, MA, USA. ¹¹⁷Department of Surgery, Jimma University, Jimma, Ethiopia. ¹¹⁸Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. ¹¹⁹School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK. ¹²⁰School of Public Health, Imperial College London, London, UK. ¹²¹Department of Regulatory Affairs, NSF International, Ann Arbor, GA, USA. ¹²²Department of Regulatory Affairs, Amarex Clinical Research, Germantown, MD, USA. ¹²³Department of Public Health, North Dakota State University, Fargo, ND, USA. ¹²⁴Global Health Neurology Lab, NSW Brain Clot Bank, Sydney, NSW, Australia. ¹²⁵Department of Neurology and Neurophysiology, South West Sydney Local Health District and Liverpool Hospital, Sydney, NSW, Australia. ¹²⁶Medical Lab Technology, Chandigarh University, Mohali, India. ¹²⁷Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, India. ¹²⁸Department of Health Behaviour, Environment and Social Medicine, Universitas Gadjah Mada (Gadjah Mada University), Sleman, Indonesia. ¹²⁹Center of Health and Behavior and Promotion, Universitas Gadjah Mada (Gadjah Mada University), Sleman, Indonesia. ¹³⁰Department of Medicine, Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada. ¹³¹Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada. ¹³²Ophthalmology Department, Moorfields Eye Hospital NHS Foundation Trust, London, UK. ¹³³International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK. ¹³⁴Department of Biopharmaceutics and Clinical Pharmacy, The University of Jordan, Amman, Jordan. ¹³⁵Department of Basic Biomedical Sciences, University of Sharjah, Sharjah, United Arab Emirates. ¹³⁶Harvard Business School, Harvard University, Boston, MA, USA. ¹³⁷School of Sciences, University of Minho, Braga, Portugal. ¹³⁸Association of Licensed Optometry Professionals, Linda-a-Velha, Portugal. ¹³⁹College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, QLD, Australia. ¹⁴⁰Public Health Department, University of Mataram, Mataram, Indonesia. ¹⁴¹Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. ¹⁴²Department of Community Medicine, Datta Meghe Institute of Medical Sciences, Sawangi, India. ¹⁴³Center for Biomedicine and Community Health, VNU-International School, Hanoi, Viet Nam. ¹⁴⁴Therapeutic and Diagnostic Technologies, Cooperativa de Ensino Superior Politécnico e Universitário (Polytechnic and University Higher Education Cooperative), Gandra, Portugal. ¹⁴⁵Institute for Research and Innovation in Health, University of Porto, Porto, Portugal. ¹⁴⁶Department of Addiction Medicine, Haukland University Hospital, Bergen, Norway. ¹⁴⁷Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. ¹⁴⁸Ophthalmology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ¹⁴⁹Ophthalmology Department, Emergency University Hospital Bucharest, Bucuresti, Romania. ¹⁵⁰Department of Radiology, Tabriz University of Medical Sciences, Tabriz, Iran. ¹⁵¹2nd University Ophthalmology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece. ¹⁵²Ophthalmology Department, University of Thessaly, Thessaly, Greece. ¹⁵³Department of Radiology, Iran University of Medical Sciences, Tehran, Iran. ¹⁵⁴Tehran University of Medical Science, Tehran University of Medical Sciences, Tehran, Iran. ¹⁵⁵Epidemiology Branch, National Institute of Health, Durham, NC, USA. ¹⁵⁶St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK. ¹⁵⁷Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece. ¹⁵⁸Department of Community Medicine, Chettinad Academy of Research and Education, Chennai, India. ¹⁵⁹Department of Human Physiology, University of Gondar, Gondar, Ethiopia. ¹⁶⁰Development of Research and Technology Center, Ministry of Health and Medical Education, Tehran, Iran. ¹⁶¹Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA. ¹⁶²Institute for Health Care Policy and Innovation, University of Michigan, Ann Arbor, MI, USA. ¹⁶³Department of Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria. ¹⁶⁴Faculty of Public Health, University of Ibadan, Ibadan, Nigeria. ¹⁶⁵Department of Biological Sciences, University of Medical Sciences, Ondo, Ondo, Nigeria. ¹⁶⁶Biomedical Informatics and Medical Statistics Department, Alexandria University, Alexandria, Egypt. ¹⁶⁷Faculty of Medicine, University of Tripoli, Tripoli, Libya. ¹⁶⁸Department of Ophthalmology, University of California Los Angeles, Los Angeles, CA, USA. ¹⁶⁹Department of Nursing, Wolkite University, Wolkite, Ethiopia. ¹⁷⁰Research Centre for Healthcare and Community, Coventry University, Coventry, UK. ¹⁷¹Department of Oral Biology, The University of Lahore, Lahore, Pakistan. ¹⁷²Department of Nutrition and Dietetics, National University of Medical Sciences (NUMS), Rawalpindi, Pakistan. ¹⁷³School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. ¹⁷⁴Endocrinology and Metabolism Research Institute, Non-Communicable Diseases Research Center (NCDRC), Tehran, Iran. ¹⁷⁵Department of Environmental Health Engineering, Isfahan University of Medical Sciences, Isfahan, Iran. ¹⁷⁶Department of Social medicine and epidemiology, Guilan University of Medical Sciences, Rasht, Iran. ¹⁷⁷University Eye Clinic, University of Genoa, Genoa, Italy. ¹⁷⁸Department of Nursing, Wollega University, Nekemte, Ethiopia. ¹⁷⁹Institute of Health sciences, Department of Public Health, Wollega University, Nekemte, Ethiopia. ¹⁸⁰Department of Mathematics, Imperial College London, London, UK. ¹⁸¹Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran. ¹⁸²Emergency Department, Isfahan University of Medical Sciences, Isfahan, Iran. ¹⁸³Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L'Aquila, L'Aquila, Italy. ¹⁸⁴Department of Neuroscience, Hospital Santa Maria delle Croci, Ravenna, Italy. ¹⁸⁵Child Survival Unit, Centre for African Newborn Health and Nutrition, Ibadan, Nigeria. ¹⁸⁶Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Nagpur, India. ¹⁸⁷Health Sciences department of Oncology Nursing, Haramaya University, Harar, Ethiopia. ¹⁸⁸Department of Midwifery, Adigrat University, Adigrat, Ethiopia. ¹⁸⁹Department of Environmental Health, Wollo University, Dessie, Ethiopia. ¹⁹⁰Department of Health, Policy Research Institute, Mekelle, Ethiopia. ¹⁹¹Simon Fraser University, Mekelle, Ethiopia. ¹⁹²Department of Nursing, Aksum University, Aksum, Ethiopia. ¹⁹³Department of Nursing, Mekelle University, Mekelle, Ethiopia. ¹⁹⁴School of Public Health, Wolaita Sodo University, Sodo, Ethiopia. ¹⁹⁵Eye Research Center, Iran University of Medical Sciences, Tehran, Iran. ¹⁹⁶Ophthalmology Department, Tehran University of Medical Sciences, Tehran, Iran. ¹⁹⁷Department of Radiology, Mayo Clinic, Rochester, MN, USA. ¹⁹⁸Health Systems and Policy Research Department, Indian Institute of Public Health, Gandhinagar, India. ¹⁹⁹Department of Genetics, Sana Institute of Higher Education, Sari, Iran. ²⁰⁰Universal Scientific Education and Research Network (USERN), Kermanshah University of Medical Sciences, Kermanshah, Iran. ²⁰¹Toxicology Department, Shriram Institute for Industrial Research, Delhi, India. ²⁰²School of Medicine, Deakin University, Geelong, VIC, Australia. ²⁰³Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, NSW, Australia. ²⁰⁴Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia. ²⁰⁵Department of Radiology, Massachusetts General Hospital, Boston, MA, USA. ²⁰⁶Obesity Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ²⁰⁷Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

²⁰⁸Department of Ophthalmology, Thomas Jefferson University, Philadelphia, PA, USA. ²⁰⁹Ophthalmology, University of California San Diego, La Jolla, CA, USA. ²¹⁰Brain and Behavioral Sciences Program, University of Georgia, Athens, GA, USA. ²¹¹Department of Pharmaceutical Technology, University of Dhaka, Dhaka, Bangladesh. ²¹²Department of Ophthalmology, Iran University of Medical Sciences, Karaj, Iran. ²¹³Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ²¹⁴Chapter of Addiction Medicine, University of Sydney, Sydney, NSW, Australia. ²¹⁵Department of Epidemiology, Non-Communicable Diseases Research Center (NCDRC), Tehran, Iran. ²¹⁶School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ²¹⁷Department of Pediatrics, Yonsei University College of Medicine, Seoul, South Korea. ²¹⁸Research Department, Electronic Medical Records for the Developing World, York, UK. ²¹⁹School of Social Sciences, The Apollo University, Chittoor, India. ²²⁰Institute of Research and Development, Duy Tan University, Da Nang, Viet Nam. ²²¹Department of Computer Science, University of Human Development, Sulaymaniyah, Iraq. ²²²Department of Psychology, Tsinghua University, Beijing, China. ²²³International Master Program for Translational Science, Taipei Medical University, Taipei, Taiwan. ²²⁴School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa. ²²⁵Research and Development Unit, Biomedical Research Networking Center for Mental Health Network (CiberSAM), Sant Boi de Llobregat, Spain. ²²⁶Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le Bretonneux, France. ²²⁷Department of Immunology, Kerman University of Medical Sciences, Kerman, Iran. ²²⁸Department of Immunology, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. ²²⁹The World Academy of Sciences UNESCO, Trieste, Italy. ²³⁰Shaanxi University of Technology, Hanzhong, China. ²³¹Department of Biochemistry, Government Medical College, Mysuru, India. ²³²Zoonoses Research Center, Islamic Azad University, Karaj, Iran. ²³³Department of Clinical Sciences, Jahrom University of Medical Sciences, Jahrom, Iran. ²³⁴Department of Community Medicine, Manipal Academy of Higher Education, Mangalore, India. ²³⁵Department of Economics, National Open University, Benin City, Nigeria. ²³⁶Department of Environmental and Occupational Health, University of Gondar, Gondar, Ethiopia. ²³⁷Social Determinants of Health Research Center, Gonabad University of Medical Sciences, Gonabad, Iran. ²³⁸Manipal Institute of Management, Manipal Academy of Higher Education, Manipal, India. ²³⁹Save Sight Institute, University of Sydney, Sydney, NSW, Australia. ²⁴⁰Sydney Eye Hospital, South Eastern Sydney Local Health District, Sydney, NSW, Australia. ²⁴¹School of Health Professions and Human Services, Hofstra University, Hempstead, NY, USA. ²⁴²Department of Anesthesiology, Montefiore Medical Center, Bronx, NY, USA. ²⁴³Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ²⁴⁴International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria. ²⁴⁵Julius Centre for Health Sciences and Primary Care, Utrecht University, Utrecht, Netherlands. ²⁴⁶Department of Public Health, Werabe University, Werabe, Ethiopia. ²⁴⁷Department of Public Health, Jordan University of Science and Technology, Irbid, Jordan. ²⁴⁸Amity Institute of Forensic Sciences, Amity University, Noida, India. ²⁴⁹Department of Basic Medical Sciences, Yarmouk University, Irbid, Jordan. ²⁵⁰Global Consortium for Public Health Research, Datta Meghe Institute of Higher Education and Research, Wardha, India. ²⁵¹Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ²⁵²School of Traditional Chinese Medicine, Xiamen University Malaysia, Sepang, Malaysia. ²⁵³School of Health Sciences, Kristiania University College, Oslo, Norway. ²⁵⁴Department of International Health and Sustainable Development, Tulane University, New Orleans, LA, USA. ²⁵⁵Department of Nursing and Health Promotion, Oslo Metropolitan University, Oslo, Norway. ²⁵⁶Independent Consultant, Jakarta, Indonesia. ²⁵⁷San Juan de Dios Sanitary Park, Barcelona, Spain. ²⁵⁸Department of Anthropology, Panjab University, Chandigarh, India. ²⁵⁹Department of Health Policy and Strategy, Foundation for People-centric Health Systems, New Delhi, India. ²⁶⁰SD Gupta School of Public Health, Indian Institute of Health Management Research University, Jaipur, India. ²⁶¹Department of Physiotherapy, Universitas Aisyiyah Yogyakarta, Yogyakarta, Indonesia. ²⁶²Institute of Allied Health Sciences, National Cheng Kung University, Tainan, Taiwan. ²⁶³Indian Council of Medical Research, New Delhi, India. ²⁶⁴Chief Medical Office, HelpMeSee, New York, NY, USA. ²⁶⁵Mexican Institute of Ophthalmology, Queretaro, Mexico. ²⁶⁶University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. ²⁶⁷Independent Consultant, Ho Chi Minh City, Viet Nam. ²⁶⁸College of Optometry, Nova Southeastern University, Fort Lauderdale, FL, USA. ²⁶⁹Department of Medical Science, Ajou University School of Medicine, Suwon, South Korea. ²⁷⁰Department of Precision Medicine, Sungkyunkwan University, Suwon-si, South Korea. ²⁷¹Department of Family Medicine, University of Texas, Galveston, TX, USA. ²⁷²Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. ²⁷³Department of Quantitative Health Science, Case Western Reserve University, Cleveland, OH, USA. ²⁷⁴Department of Ophthalmology, Tehran University of Medical Sciences, Tehran, Iran. ²⁷⁵Department of Food Hygiene and Safety, Qazvin University of Medical Sciences, Qazvin, Iran. ²⁷⁶Department of Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, India. ²⁷⁷Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. ²⁷⁸Faculty of Humanities and Health Sciences, Curtin University, Malaysia, Sarawak, Malaysia. ²⁷⁹Jeffrey Cheah School of Medicine and Health Sciences, Monash University, Subang Jaya, Malaysia. ²⁸⁰Department of Ophthalmology, Princess of Wales Hospital, Wales, UK. ²⁸¹School of Optometry and Vision Sciences, Cardiff University, Cardiff, UK. ²⁸²Department of Public Health, Arba Minch University, Arba Minch, Ethiopia. ²⁸³Department of Nursing, Arba Minch University, Arba Minch, Ethiopia. ²⁸⁴University Centre Varazdin, University North, Varazdin, Croatia. ²⁸⁵Department of Medical Physiology, Madda Walabu University, Bale-Goba, Ethiopia. ²⁸⁶Medical School, Macquarie University, Sydney, NSW, Australia. ²⁸⁷Molecular Biology Unit, Sirius Training and Research Centre, Khartoum, Sudan. ²⁸⁸Bio-Statistical and Molecular Biology Department, Sirius Training and Research Centre, Khartoum, Sudan. ²⁸⁹University of Gondar, University of Gondar, Gondar, Ethiopia. ²⁹⁰Department of Biostatistics, Shiraz University of Medical Sciences, Shiraz, Iran. ²⁹¹School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, QLD, Australia. ²⁹²Non-communicable Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran. ²⁹³Iran University of Medical Sciences, Tehran, Iran. ²⁹⁴Non-communicable Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran. ²⁹⁵Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece. ²⁹⁶Discipline of Optometry, University of KwaZulu-Natal, Durban, South Africa. ²⁹⁷College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia. ²⁹⁸Department of Engineering, Western Sydney University, Sydney, NSW, Australia. ²⁹⁹University Institute of Public Health, The University of Lahore, Lahore, Pakistan. ³⁰⁰Department of Dental Public Health, King Abdulaziz University, Jeddah, Saudi Arabia. ³⁰¹Department of Health Policy and Oral Epidemiology, Harvard University, Boston, MA, USA. ³⁰²Independent Consultant, Tehran, Iran. ³⁰³Department of Internal Medicine, Ardabil University of Medical Science, Ardabil, Iran. ³⁰⁴Department of Medical Laboratory Sciences, Adigrat University, Adigrat, Ethiopia. ³⁰⁵Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA. ³⁰⁶Department of Medical Engineering, University of South Florida, Tampa, FL, USA. ³⁰⁷Cardiovascular Research Department, Methodist Hospital, Merrillville, IL, USA. ³⁰⁸Department of Surgery, Danang Family Hospital, Danang, Viet Nam. ³⁰⁹Department of General Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam. ³¹⁰International Islamic University Islamabad, Islamabad, Pakistan. ³¹¹Microbiology and Molecular Genetics, The Women University Multan, Multan, Pakistan. ³¹²Department of Physiology, University of Benin, Edo, Nigeria. ³¹³Department of Physiology, Benson Idahosa University, Benin City, Nigeria. ³¹⁴Department of Veterinary Public Health and Preventive Medicine, University of Ilorin, Ilorin, Nigeria. ³¹⁵Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada. ³¹⁶Department of Psychiatry, University of Lagos, Lagos, Nigeria. ³¹⁷Department of Nursing Science, Bowen University, Iwo, Nigeria. ³¹⁸Department of Pharmacology and Therapeutics, University of Nigeria Nsukka, Enugu, Nigeria. ³¹⁹Department of Pharmacotherapy and Pharmaceutical Care, Medical University of Warsaw, Warsaw, Poland. ³²⁰School of Medicine, Western Sydney University, Campbelltown, NSW, Australia. ³²¹Department of Optometry and Vision Science, University of KwaZulu-Natal, KwaZulu-Natal, South Africa. ³²²Laboratory of Public Health Indicators Analysis and Health Digitalization, Moscow Institute of Physics and Technology, Dolgoprudny, Russia. ³²³Department of Medicine, University of Ibadan, Ibadan, Nigeria. ³²⁴Department of Medicine, University College Hospital, Ibadan, Ibadan, Nigeria. ³²⁵Department of Forensic Medicine and Toxicology, Kasturba Medical College, Mangalore, Mangalore, India. ³²⁶School of Medicine, Iran University of Medical Sciences, Tehran, Iran. ³²⁷Research Department, Nepal Health Research Council, Kathmandu, Nepal. ³²⁸Research Department, Public Health Research Society Nepal, Kathmandu, Nepal. ³²⁹Global Health Governance Programme, University of Edinburgh, Edinburgh, UK. ³³⁰School of Dentistry, University of Leeds, Leeds, UK. ³³¹Department of Internal Medicine, Advent Health, Palm Coast, FL, USA. ³³²Department of Hospital Medicine, Sound Physicians, Palm Coast, FL, USA. ³³³Department of Genetics, Yale University, New Haven, CT, USA. ³³⁴Department of Development Studies, International Institute for Population Sciences, Mumbai, India. ³³⁵Department of Statistics and Econometrics, Bucharest University of Economic Studies, Bucharest, Romania. ³³⁶Medical School, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam. ³³⁷Department of Neonatology, Case Western Reserve University, Cleveland, OH, USA. ³³⁸Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Jodhpur, India. ³³⁹Department of Health Sciences, Cihan University Sulaimaniya, Sulaymaniyah, Iraq. ³⁴⁰Cihan University Sulaimaniya Research Center (CUSRC), Sulaymaniyah, Iraq. ³⁴¹Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran. ³⁴²Manipal TATA Medical College, Manipal Academy of Higher Education, Manipal, India. ³⁴³Department of Population Science and Human Resource Development, University of Rajshahi, Rajshahi, Bangladesh. ³⁴⁴Department of Community Medicine, Mahatma Gandhi Medical College and Research Institute, Puducherry, India. ³⁴⁵Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan. ³⁴⁶Department of Health Behaviour, Environment, and Social Medicine, Gajah Mada University, Yogyakarta, Indonesia. ³⁴⁷Department Biological Sciences, King Abdulaziz University, Jeddah, Egypt. ³⁴⁸Department of Protein Research, Research and Academic Institution, Alexandria, Egypt. ³⁴⁹Department of Labour, Directorate of Factories, Government of West Bengal, Kolkata, India. ³⁵⁰Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran. ³⁵¹Infectious Diseases Research Center, Gonabad University of Medical Sciences, Gonabad, Iran. ³⁵²Department of Epidemiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ³⁵³College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. ³⁵⁴Multidisciplinary Laboratory Foundation University School of Health Sciences (FUSH), Foundation University, Islamabad, Pakistan. ³⁵⁵International Center of Medical Sciences Research (ICMSR), Islamabad, Pakistan. ³⁵⁶Ophthalmic Epidemiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ³⁵⁷Faculty of Medicine, Bioscience and Nursing, MAHSA University, Selangor, Malaysia. ³⁵⁸Interdisciplinary Research Centre

in Biomedical Materials (IRCBM), COMSATS Institute of Information Technology, Lahore, Pakistan. ³⁵⁹Research Center for Immunodeficiencies, Tehran University of Medical Sciences, Tehran, Iran. ³⁶⁰Sharjah Institute of Medical Sciences, University of Sharjah, Sharjah, United Arab Emirates. ³⁶¹Clinical Sciences Department, University of Sharjah, Sharjah, United Arab Emirates. ³⁶²Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. ³⁶³Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. ³⁶⁴University of Warwick, Coventry, UK. ³⁶⁵Institute for Employment Research, Nuremberg, Germany. ³⁶⁶Medical Laboratory, Azad University of Medical Sciences, Tehran, Iran. ³⁶⁷Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran. ³⁶⁸Advanced Therapy Medicinal Products Department, Royan Institution, Tehran, Iran. ³⁶⁹Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. ³⁷⁰School of Public Health, Taipei Medical University, Taipei, Taiwan. ³⁷¹Department of Anatomy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates. ³⁷²Department of Entomology, Ain Shams University, Cairo, Egypt. ³⁷³Medical Ain Shams Research Institute (MASRI), Ain Shams University, Cairo, Egypt. ³⁷⁴Department of Pharmacology and Research, All India Institute of Medical Sciences, Jodhpur, India. ³⁷⁵Indira Gandhi Medical College and Research Institute, Puducherry, India. ³⁷⁶Department of Public Health Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA. ³⁷⁷Market Access Division, Bayer, Istanbul, Türkiye. ³⁷⁸Comprehensive Ophthalmology, NOOR Eye Training Center, International Assistance Mission, Kabul, Afghanistan. ³⁷⁹Research Department, Online Research Club, Nagasaki, Japan. ³⁸⁰Faculty of Dentistry, AIMST University, Bedong, Malaysia. ³⁸¹Department of Medicine and Surgery, Government Doon Medical College, Dehradun, India. ³⁸²National Heart, Lung, and Blood Institute, National Institute of Health, Rockville, MD, USA. ³⁸³Medical Research Center, Kateb University, Kabul, Afghanistan. ³⁸⁴Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore, Lahore, Pakistan. ³⁸⁵Research Centre for Health Sciences (RCHS), The University of Lahore, Lahore, Pakistan. ³⁸⁶Centre of Medical and Bio Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates. ³⁸⁷Independent Consultant, Karachi, Pakistan. ³⁸⁸Department of Ophthalmology, Harvard Medical School, Boston, MA, USA. ³⁸⁹Ophthalmic Research Center (ORC), Shahid Beheshti University of Medical Sciences, Tehran, Iran. ³⁹⁰National Institute of Infectious Diseases, Tokyo, Japan. ³⁹¹Department of Veterinary Public Health and Preventive Medicine, Usmanu Danfodiyo University, Sokoto, Sokoto, Nigeria. ³⁹²Department of Medical-Surgical Nursing, Mazandaran University of Medical Sciences, Sari, Iran. ³⁹³Department of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia. ³⁹⁴Unit of Basic Medical Sciences, University of Khartoum, Khartoum, Sudan. ³⁹⁵Department of Medical Microbiology and Infectious Diseases, Erasmus University, Rotterdam, Netherlands. ³⁹⁶Family, Health Promotion, and Life Course Department, Pan American Health Organization, Washington, DC, USA. ³⁹⁷School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. ³⁹⁸Medicine Service, US Department of Veterans Affairs (VA), Birmingham, AL, USA. ³⁹⁹Department of Radiodiagnosis, All India Institute of Medical Sciences, Bathinda, India. ⁴⁰⁰Department of Ophthalmology, Hywel Dda University Health Board, Llanelli, UK. ⁴⁰¹Directive Board, Associação de Profissionais Licenciados de Optometria (Association of Licensed Optometry Professionals), Linda-a-Velha, Portugal. ⁴⁰²Division of Community Medicine, International Medical University, Kuala Lumpur, Malaysia. ⁴⁰³Federal Research Institute for Health Organization and Informatics of the Ministry of Health (FRIHOI), Moscow, Russia. ⁴⁰⁴School of Nursing and Midwifery, Debre Berhan University, Debre Berhan, Ethiopia. ⁴⁰⁵Faculty of Public Health, Universitas Sam Ratulangi, Manado, Indonesia. ⁴⁰⁶Medical School, University of Crete, Heraklion, Greece. ⁴⁰⁷Institute of Soil and Environmental Sciences, University of Agriculture, Faisalabad, Faisalabad, Pakistan. ⁴⁰⁸Medical Genomics Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. ⁴⁰⁹Department of Life Sciences, University of Management and Technology, Lahore, Pakistan. ⁴¹⁰Clinical Cancer Research Center, Milad General Hospital, Tehran, Iran. ⁴¹¹Department of Microbiology, Islamic Azad University, Tehran, Iran. ⁴¹²Department of Community Medicine, Rajarata University of Sri Lanka, Anuradhapura, Sri Lanka. ⁴¹³Department of Ophthalmology Research, Queen Mamohato Memorial Hospital, Maseru, Lesotho. ⁴¹⁴Ophthalmology Unit, Bahir Dar University, Bahir dar, Ethiopia. ⁴¹⁵Department of Cancer Epidemiology and Prevention Research, Alberta Health Services, Calgary, AB, Canada. ⁴¹⁶Department of Oncology, University of Calgary, Calgary, AB, Canada. ⁴¹⁷Department of Health Management, Süleyman Demirel Üniversitesi (Süleyman Demirel University), Isparta, Türkiye. ⁴¹⁸Department of Pediatrics, Kyung Hee University, Seoul, South Korea. ⁴¹⁹Department of Neuropsychopharmacology, National Center of Neurology and Psychiatry, Kodaira, Japan. ⁴²⁰Department of Public Health, Juntendo University, Tokyo, Japan. ⁴²¹Macquarie Medical School, Macquarie University, Sydney, NSW, Australia. ⁴²²Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA. ⁴²³Addictology Department, Russian Medical Academy of Continuous Professional Education, Moscow, Russia. ⁴²⁴College of Traditional Chinese Medicine, Hebei University, Baoding, China. ⁴²⁵Department of Ophthalmology, Iran University of Medical Sciences, Tehran, Iran. ⁴²⁶Department of Biochemistry and Pharmacogenomics, Medical University of Warsaw, Warsaw, Poland. ⁴²⁷These authors contributed equally: Jaimie D. Steinmetz, Rupert R. A. Bourne.

[✉]email: furtadojm@gmail.com